133P Personalized circulating tumor DNA (ctDNA) during neoadjuvant therapy (NAT) to predict response in patients (pts) with early-stage breast cancer (eBC)
- Resource Type
- Abstract
- Source
- In
ESMO Open May 2023 8(1) Supplement 4 - Subject
- Language
- ISSN
- 2059-7029